NASDAQ:CLBS • US1280582032
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CALADRIUS BIOSCIENCES INC (CLBS).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2021-03-03 | Brookline Capital | Maintains | Buy |
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 22.49M | 32.797M -100.00% | 4.08M | 6.12M 50.00% | 9M 47.06% | 13.5M 50.00% | |||||||
| EBITDA YoY % growth | -48.89M | N/A 40.58% | N/A 6.30% | -17.34M 38.42% | N/A -19.48% | -19.686M 4.72% | -31.008M -51.95% | -28.56M 1.50% | -24.174M 15.36% | -24.99M -3.38% | -25.968M -3.91% | -27.523M -5.99% | |
| EBIT YoY % growth | -51.58M | -32.696M 42.80% | -27.424M 6.47% | -17.952M 38.44% | -20.37M -18.28% | -20.289M 4.71% | -30.86M -51.74% | -28.56M 1.69% | -27.322M 4.33% | -28.878M -5.70% | -28.119M 2.63% | -27.928M 0.68% | |
| Operating Margin | -229.35% | -99.69% | N/A | N/A | N/A | N/A | N/A | N/A | -669.66% | -471.87% | -312.44% | -206.87% | |
| EPS YoY % growth | -14.80 | -5.16 64.53% | -2.15 59.43% | -1.79 15.02% | -1.77 -3.31% | -0.83 75.94% | -0.55 -15.56% | -0.43 17.62% | -0.37 14.29% | -0.34 8.33% | -0.37 -9.13% | -0.41 -11.31% |
All data in USD
| Q3 / 22 | Q4 / 22 | |
|---|---|---|
| EPS Q2Q % growth | -0.12 -2.00% | -0.12 -11.27% |
| Revenue Q2Q % growth | ||
| EBITDA Q2Q % growth | -7.242M -4.64% | -7.752M -14.10% |
| EBIT Q2Q % growth | -7.853M -12.71% | -8.252M -20.48% |
All data in USD
8 analysts have analysed CLBS and the average price target is 4.59 USD. This implies a price increase of 976.45% is expected in the next year compared to the current price of 0.4264.
CALADRIUS BIOSCIENCES INC (CLBS) will report earnings on 2022-11-02.
The consensus EPS estimate for the next earnings of CALADRIUS BIOSCIENCES INC (CLBS) is -0.12 USD and the consensus revenue estimate is 0 USD.